Products - Children and teenagers | Topic

Showing 165 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
28 July 2021
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTE25)
Product type:
Guidance
Programme:
Health technology evaluation
Published:
7 May 2025
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
1 May 2025
Published:
23 June 2015
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Last updated:
8 April 2025
Published:
10 October 2018
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 March 2025
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 February 2025
Epilepsies in children, young people and adults (NG217)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
30 January 2025
Published:
27 April 2022
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 January 2025
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 January 2025
Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years (NG247)
Product type:
Guidance
Programme:
NICE guideline
Published:
15 January 2025
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 November 2024
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 January 2024
Risdiplam for treating spinal muscular atrophy (TA755)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
15 December 2023
Published:
16 December 2021
Transient loss of consciousness ('blackouts') in over 16s (CG109)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
21 November 2023
Published:
25 August 2010
Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment (HTE3)
Product type:
Guidance
Programme:
Health technology evaluation
Last updated:
5 September 2023
Published:
8 February 2023
Otitis media with effusion in under 12s (NG233)
Product type:
Guidance
Programme:
NICE guideline
Published:
30 August 2023
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2023
Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people (IPG765)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2023
Atopic eczema in under 12s: diagnosis and management (CG57)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
7 June 2023
Published:
12 December 2007
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
11 May 2023
Published:
1 August 2015
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
1 March 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
13 January 2023
Published:
9 March 2022
Self-harm: assessment, management and preventing recurrence (NG225)
Product type:
Guidance
Programme:
NICE guideline
Published:
7 September 2022
Urinary tract infection in under 16s: diagnosis and management (NG224)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 July 2022
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 July 2022
Social, emotional and mental wellbeing in primary and secondary education (NG223)
Product type:
Guidance
Programme:
NICE guideline
Published:
6 July 2022
Vertebral body tethering for idiopathic scoliosis in children and young people (IPG728)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
29 June 2022
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
5 May 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
28 March 2022
Palforzia for treating peanut allergy in children and young people (TA769)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2021
Fever in under 5s: assessment and initial management (NG143)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
26 November 2021
Published:
7 November 2019
Looked-after children and young people (NG205)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 October 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 October 2021
Babies, children and young people's experience of healthcare (NG204)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 August 2021
Bronchiolitis in children: diagnosis and management (NG9)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
9 August 2021
Published:
1 June 2015
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Autism spectrum disorder in under 19s: support and management (CG170)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
14 June 2021
Published:
28 August 2013
Cannabis-based medicinal products (NG144)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
22 March 2021
Published:
11 November 2019
Eating disorders: recognition and treatment (NG69)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
16 December 2020
Published:
23 May 2017
Intravenous fluid therapy in children and young people in hospital (NG29)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
11 June 2020
Published:
9 December 2015
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2019
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
27 November 2019
Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
9 October 2019
Published:
14 January 2015
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
13 September 2019
Published:
14 March 2018
End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
25 July 2019
Published:
7 December 2016
Depression in children and young people: identification and management (NG134)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 June 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2019
Cough (acute): antimicrobial prescribing (NG120)
Product type:
Guidance
Programme:
NICE guideline
Published:
7 February 2019
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2018
Learning disabilities and behaviour that challenges: service design and delivery (NG93)
Product type:
Guidance
Programme:
NICE guideline
Published:
28 March 2018
Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
20 December 2017
Published:
28 September 2011
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Child abuse and neglect (NG76)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 October 2017
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
9 October 2017
Published:
22 July 2009
Faltering growth: recognition and management of faltering growth in children (NG75)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 September 2017
Developmental follow-up of children and young people born preterm (NG72)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 August 2017
Constipation in children and young people: diagnosis and management (CG99)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
13 July 2017
Published:
26 May 2010
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2017
Antisocial behaviour and conduct disorders in children and young people: recognition and management (CG158)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
19 April 2017
Published:
27 March 2013
Cerebral palsy in under 25s: assessment and management (NG62)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 January 2017
Spasticity in under 19s: management (CG145)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
29 November 2016
Published:
25 July 2012
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
26 October 2016
Published:
23 January 2013
Harmful sexual behaviour among children and young people (NG55)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 September 2016
Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures (CG64)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
8 July 2016
Published:
17 March 2008
Transition from children’s to adults’ services for young people using health or social care services (NG43)
Product type:
Guidance
Programme:
NICE guideline
Published:
24 February 2016
Children’s attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care (NG26)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 November 2015
Contraceptive services for under 25s (PH51)
Product type:
Guidance
Programme:
Public health guideline
Published:
26 March 2014
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2013
Social and emotional wellbeing: early years (PH40)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 October 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Food allergy in under 19s: assessment and diagnosis (CG116)
Product type:
Guidance
Programme:
Clinical guideline
Published:
23 February 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 January 2011
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
Product type:
Guidance
Programme:
Clinical guideline
Published:
15 December 2010
Unintentional injuries in the home: interventions for under 15s (PH30)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 November 2010
Unintentional injuries on the road: interventions for under 15s (PH31)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 November 2010
Unintentional injuries: prevention strategies for under 15s (PH29)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 November 2010
Bedwetting in under 19s (CG111)
Product type:
Guidance
Programme:
Clinical guideline
Published:
27 October 2010
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2010
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
Product type:
Guidance
Programme:
Clinical guideline
Published:
22 April 2009
Physical activity for children and young people (PH17)
Product type:
Guidance
Programme:
Public health guideline
Published:
28 January 2009
Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (IPG232)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 September 2007
Improving outcomes in children and young people with cancer (CSG7)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
24 August 2005
Balloon dilatation of systemic to pulmonary arterial shunts in children (IPG77)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children (IPG76)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Vagus nerve stimulation for refractory epilepsy in children (IPG50)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2004
Somapacitan for treating growth hormone deficiency in people 3 to 17 years [ID6178]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 May 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2025
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]
Status:
In development | In consultation
Programme:
Highly specialised technologies guidance
Consultation end date:
6 June 2025
Expected publication date:
17 September 2025
Digital self-help for people with eating disorders: early value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
13 November 2025
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TSID10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [TSID10237]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [TSID12142]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Paediatric lymphatic interventions (mainly Percutaneous thoracic duct embolisation) for Chylothorax, chylous ascites, plastic bronchitis, chylopericardium, Chyluria, Protein losing enteropathy
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [TSID12187]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID12133]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and teenagers Products

Filter

Product type1 selected

Guidance programme

Status

New and updated

Showing 165 products

Product type
1 selected